AlmirallShare, the open innovation platform of Almirall, SA (ALM), announces two new collaborations with the Research Institute Foundation of the Hospital de la Santa Creu i Sant Pau and the University of South Australia (Unisa) with the aim of finding new ways of treating skin cancer and atopic dermatitis.
The project led by Dr. Lluís Puig, director of the Dermatology Service at the Hospital de Sant Pau, and Prof. Sílvia Vidal, coordinator of the Inflammatory Diseases Research Group at the Sant Pau-IIB Sant Pau Research Institute, will focus on understanding the biomarkers that operate in the different phases of atopic dermatitis and in response to different systemic therapies. The relationship between the composition of the skin’s immune cells, skin transcriptoma and systemic biomarkers in patients with atopic dermatitis will be investigated. “We strongly believe that this collaboration will drive new discoveries in atopic dermatitis and is a further step in future research into new treatments for skin health. We are very happy to join forces with a leading company in medical dermatology as an admiral,” agree Dr. Luis Puig and Prof. Sílvia Vidal.
The collaboration with the group of Prof. Tarl Prow, research professor at the Future Industries Institute of the University of South Australia, focuses on the generation of knowledge on a common type of skin tumour. The aim is to elucidate the molecular mechanisms underlying squamous cell carcinoma and its modulation through specific treatment. The group has a strong commitment to the fight against skin cancer and has developed innovative technologies with clinical application that encourage the topical administration of medicines to the skin.
